The Technical Analyst
Palisade Bio, Inc. [PALI]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Palisade Bio, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
7.26% $6.35
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 77.02 mill |
| EPS: | 0.320 |
| P/E: | 19.84 |
| Earnings Date: | Mar 21, 2024 |
| SharesOutstanding: | 12.13 mill |
| Avg Daily Volume: | 1.074 mill |
| RATING 2024-04-24 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 19.84 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 3.38x |
| Company: PE 19.84 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$13.61 (114.29%) $7.26 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 5.93 - 6.77 ( +/- 6.66%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-11 | Finley John David | Buy | 5 558 | Common Stock, par value $0.01 |
| 2024-03-11 | Finley John David | Sell | 5 558 | Restricted Stock Units |
| 2024-02-09 | Neal James R | Buy | 12 160 | Common Stock Options |
| 2024-02-09 | Neal James R | Buy | 5 820 | Common Stock, par value $0.01 |
| 2024-02-09 | Neal James R | Buy | 6 880 | Common Stock Options |
| INSIDER POWER |
|---|
| 33.99 |
| Last 100 transactions |
| Buy: 569 716 | Sell: 281 847 |
Forecast:
16:00 - $6.35
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $6.35
Forecast 2: 16:00 - $6.35
Forecast 3: 16:00 - $6.35
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $6.35 (7.26% ) |
| Volume | 0.457 mill |
| Avg. Vol. | 1.074 mill |
| % of Avg. Vol | 42.58 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PALI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $0.446 | N/A | Active |
|---|
PALI
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Latest Press Releases
2024-04-23 08:30:00 - Press Release
Palisade Bio Enters Into Strategic Collaboration With Strand Life Sciences to Advance Precision Medicine Approach
– collaboration grants palisade bio access to cutting-edge expertise and tools in bioinformatics – partnership marks a significant value-driving milestone in palisade bio's mission to redefine uc treatment through targeted interventions based on pde4-related biomarkers carlsbad, ca, april 23, 2024 (globe newswire) -- palisade bio, inc. (nasdaq: pali) (“palisade”, “palisade bio” or the “company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has entered into a transformative strategic collaboration with strand life sciences, a leading bioinformatics specialist, aimed at advancing precision medicine for ulcerative colitis (uc) therapy...
2024-04-16 08:30:00 - Press Release
Palisade Bio Successfully Demonstrates Bioactivation Of Pali-2108 In Ex-vivo Study Of Normal Healthy And Ulcerative Colitis Patients' Stool
Company continues advancing ongoing development of targeted therapies for ulcerative colitis (uc) carlsbad, ca, april 16, 2024 (globe newswire) -- palisade bio, inc. (nasdaq: pali) (“palisade”, “palisade bio” or the “company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, announced today the successful completion of its analysis evaluating ex-vivo bioactivation of pali-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (pde4) inhibitor prodrug in development for patients affected by uc. these findings demonstrated that pali-2108 exhibited efficient ex-vivo conversion into its active pde4 inhibitor form in stool samples from both normal healthy volunteers and patients with uc.
2024-04-11 09:15:00 - Press Release
Palisade Bio To Participate In The Virtual Investor Lunch Break Event
– live webcast with members of palisade bio management on tuesday, april 16 th at 12:00 pm et
2024-04-10 08:15:00 - Press Release
Palisade Bio Presents Development Overview Of Pali-2108 At The Ibd Innovate: Product Development For Crohn's & Colitis™
– pali-2108 in development for the treatment of moderate-to-severe ulcerative colitis (uc) advancing towards phase 1 clinical study before year end
2024-04-03 17:30:00 - Press Release
Palisade Bio Announces 1-for-15 Reverse Stock Split
Carlsbad, ca, april 03, 2024 (globe newswire) -- palisade bio, inc. (nasdaq: pali), (“palisade”, “palisade bio” or the “company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced a 1-for-15 reverse split of its common stock, par value $0.01 (“common stock”), effective at 5:00 pm et on friday april 5, 2024. beginning on monday, april 8, 2024, the company's common stock will continue to trade on the nasdaq capital market (“nasdaq”) on a split adjusted basis under the trading symbol “pali,” but will trade under the following new cusip number starting april 8, 2024: 696389402.
Latest News
2024-04-23 11:09:40 - Invezz
Palisade Bio stock rallies on Strand Life Sciences partnership
Palisade Bio Inc (NASDAQ: PALI) opened roughly 50% up on Tuesday after teaming up with Strand Life Sciences. Here's what it means for Palisade Bio stock The strategic collaboration puts its patient datasets together with bioinformatics tools of the genomics software and services company.
2024-04-16 11:22:08 - InvestorPlace
Why Is Palisade Bio (PALI) Stock Up 57% Today?
Palisade Bio (NASDAQ: PALI ) stock is climbing higher on Tuesday after the clinical-stage biopharmaceutical company revealed additional data for its ulcerative colitis (UC) treatment. The big news here is Palisade Bio completing its analysis of ex-vivo bioactivation of PALI-2108.
2024-02-15 08:35:00 - GlobeNewsWire
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that its abstract has been accepted for poster presentation at DDW 2024 being held in Washington, D.C., May 18-21, 2024.
2024-01-29 14:01:45 - InvestorPlace
Why Is Palisade Bio (PALI) Stock Up 100% Today?
Biopharmaceutical company Palisade Bio (NASDAQ: PALI ) is seeing its market value skyrocket off multiple encouraging catalysts today. While PALI stock still remains an extremely risky proposition, investors are being buoyed by some key developments.
2023-09-07 10:28:39 - InvestorPlace
Why Is Palisade Bio (PALI) Stock Down 46% Today?
Palisade Bio (NASDAQ: PALI ) stock is falling on Thursday after the clinical-stage biopharmaceutical company announced a share offering. Palisade Bio is selling 2,339,398 shares of PALI stock through a registered direct offering.
2023-09-07 09:01:12 - Zacks Investment Research
Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up
Palisade (PALI) gains on entering into global licensing deal with Giiant Pharma to develop gastrointestinal therapies.
2023-09-06 10:11:00 - Market Watch
Palisade Bio's stock more than doubles on news of licensing deal with Giiant Pharma for IBD therapies
Palisade Bio Inc.'s stock PALI more than doubled in price on Wednesday, after the company announced a licensing agreement with privately held Giiant Pharma Inc. Carlsbad, Calif.-based Palisade said the license gives it exclusive worldwide rights to develop, make and commercialize Giiant's proprietary targeted prodrug platform which specializes in therapies for the IBS market.
2023-06-14 08:45:00 - GlobeNewsWire
Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
2023-05-23 11:08:31 - Zacks Investment Research
Palisade Bio, Inc. (PALI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Palisade Bio, Inc. (PALI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
2023-04-06 15:14:06 - Zacks Investment Research
Palisade (PALI) Enrolls First Patient in LB1148 Study in China
Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.